Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21295673 | 0.81 | KDM4E (0.45) | MIFGABRA1BRD4KDM4EMAPT | |
| SCHEMBL21295742 | 0.76 | NOTUM (0.40) | GPR3KDM4EMAPTALDH1A1HSD17B10 | |
| SCHEMBL14782179 | 0.75 | PDPK1 (0.46) | KDM4EMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL3667276 | 0.74 | MAPT (0.42) | KDM4EMAPTALDH1A1HSD17B10NPC1 | |
| SCHEMBL2956882 | 0.74 | GPR3 (0.37) | GPR3ALDH1A1EPAS1 | |
| SCHEMBL21295855 | 0.72 | CYP2A6 (0.45) | CYP19A1KDM4EMAPTALDH1A1HSD17B10 | |
| SCHEMBL5744633 | 0.68 | RAB9A (0.47) | KDM4EMAPTALDH1A1HSD17B10NPC1 | |
| SCHEMBL2966653 | 0.68 | KDM4E (0.35) | KDM4EMAPTALDH1A1HSD17B10TP53 | |
| SCHEMBL1013581 | 0.68 | KDM4E (0.39) | KDM4EMAPTALDH1A1HSD17B10NPC1 | |
| SCHEMBL5758421 | 0.67 | KDM4E (0.31) | KDM4EMAPTNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102858764-B | Pyrimidinyl indole compounds | HUTCHISON MEDIPHARMA SHANGHAI LTD | 2014-08-20 | — | — | CN | disclosed |
| CN-102858764-A | Pyrimidinyl indole compounds | HUTCHISON MEDIPHARMA SHANGHAI LTD | 2013-01-02 | — | — | CN | disclosed |
| CN-101309918-B | [4-(benzo[b]thiophen-2-yl)-pyrimidin-2-yl]-amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases | LILLY CO ELI | 2010-12-29 | — | — | CN | disclosed |
| CN-101309918-A | [4-(benzo[b]thiophen-2-yl)-pyrimidin-2-yl]-amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases | LILLY CO ELI (US) | 2008-11-19 | — | — | CN | disclosed |
| US-7135487-B2 | such as N-2-(4-Bromophenyl)propyl methanesulfonamide; sulfonamidation of the amine; glutamate receptor potentiators | ELI LILLY AND COMPANY (US) | 2006-11-14 | — | — | US | disclosed |
| US-7034045-B1 | Monofluoroalkyl derivatives | ELI LILLY AND COMPANY (US) | 2006-04-25 | — | — | US | disclosed |
| US-20060030599-A1 | SULPHONAMIDE DERIVATIVES | ARNOLD MACKLIN B | 2006-02-09 | — | — | US | disclosed |
| EP-1395550-B1 | CYCLOALKENYLSULFONAMIDE DERIVATIVES | LILLY CO ELI (US) | 2005-06-29 | — | — | EP | disclosed |
| US-6911476-B2 | Sulfonamide derivatives | ELI LILLY AND COMPANY (US) | 2005-06-28 | — | — | US | disclosed |
| US-6900353-B2 | Cyclopentyl sulfonamide derivatives | ELI LILLY AND COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| WO-2000006157-A1 | SULPHONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006176-A1 | AMIDOPHOSPHATE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006539-A1 | ALKENYL SULPHONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006149-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006537-A1 | N-SUBSTITUTED SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006156-A1 | AMIDE, CARBAMATE, AND UREA DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006083-A2 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| EP-0976744-A1 | Amide, carbamate, and urea derivatives having glutamate receptor function potentiating activity | ELI LILLY AND COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
| EP-0860428-A2 | Sulphonamide derivatives | ELI LILLY AND COMPANY (US) | 1998-08-26 | — | — | EP | disclosed |
| WO-1998033496-A1 | SULPHONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030599-A1 | SULPHONAMIDE DERIVATIVES | GRIN2C, GLRA2, GLRA1 | GPR3 44/4885MIF 4773/4885GABRA1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.